All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Nail psoriasis is a common manifestation in patients with psoriasis and psoriatic arthritis (PsA), affecting up to 60% of patients with psoriasis and ~80% of patients with PsA.1 Nail psoriasis is associated with lower quality of life in patients with psoriatic disease, and can be predictive of PsA development.1 The understanding of nail psoriasis is limited, due to a lack of clinical trials focused on this manifestation.2 Therefore, available treatment data of nail psoriasis have been generated from clinical trials investigating psoriasis and PsA. Here, we present the currently available systemic treatments for nail psoriasis.
In nail psoriasis, inflammation of the nail bed or matrix occurs, resulting in morphological changes. Nail psoriasis is also associated with enthesitis, which can be an early indicator of PsA and can suggest increased disease severity. In nail psoriasis, the nail bed can become discolored, with salmon patches, splinter hemorrhages, and onycholysis also occurring. The nail matrix can become pitted, with leukonychia, Beau lines, and nail crumbling.
Nail psoriasis is diagnosed by the presence of psoriatic changes in the nail. In patients with psoriatic disease, nail manifestations should be monitored continuously, as they can be a predictor of disease evolution. In the clinical trial setting, the Nail Psoriasis Severity Index (NAPSI) is used as a tool to assess nail psoriasis. With the NAPSI, each nail is divided into quadrants and scored for presence or absence of psoriatic changes (1 for presence and 0 for absence), with the scores added together to obtain a total NAPSI score, as shown in Figure 1. A modified NAPSI (mNAPSI) can also be used, which measures disease severity in each nail, but this can be difficult to carry out in a real-world setting. Physician’s Global Assessment of Fingernail Psoriasis (PGA-F) can also be used to assess nail psoriasis, with a PGA-F score ≥3 indicating moderate-to-severe nail psoriasis.
Figure 1. NAPSI score and common symptoms of nail psoriasis*
NAPSI, Nail Psoriasis Severity Index.
*Data from Kirkham, et al.1 Created with Biorender.com
There are multiple treatments available for patients with nail psoriasis. Treatment are selected based on disease severity, comorbidities, and extent of skin and joint involvement. Topical and injectable therapies are usually used in patients where only a few nails are involved, with systemic therapies used when nail psoriasis is severe. Table 1, Table 2, and Table 3 provide an overview of tumor necrosis factor alpha inhibitors,2,3,4,5 interleukin inhibitors, and other systemic therapies currently being used or investigated for nail psoriasis.
Table 1. TNF-a inhibitors used for the treatment of nail psoriasis*
Therapy2 |
FDA Approved?3,4 |
Efficacy2 |
---|---|---|
Etanercept |
PsO and PsA |
Showed efficacy in treating NP in multiple clinical trials. |
Infliximab |
PsO and PsA |
Shown to significantly improve nail involvement in patients with psoriasis in the phase III EXPRESS trial (NCT00106834). |
Adalimumab |
PsO and PsA |
Well tolerated, with improvements to NAPSI score observed in a phase III study. |
Certolizumab |
PsO and PsA |
SC administration showed efficacy in a real-life multicenter study. |
Golimumab |
PsA, rheumatoid arthritis, ankylosing spondylitis |
Improvements in mNAPSI score observed in treating NP associated with PsA. |
mNAPSI, Modified Nail Psoriasis Severity Index; NAPSI, Nail Psoriasis Severity Index; NP, nail psoriasis; PsA, psoriatic arthritis; PsO, psoriasis; SC, subcutaneous; TNF-a, tumor necrosis factor alpha. |
Table 2. IL inhibitors used for the treatment of nail psoriasis*
Therapy2 |
FDA Approved?3,4 |
Efficacy2 |
---|---|---|
Ustekinumab |
PsO and PsA |
Showed improvements in NAPSI score in both finger and toenail psoriasis; however, some trials suggest more marked improvements in the nails of the big and 2nd toes. |
Ixekizumab |
PsO and PsA |
Showed efficacy in treating NP and greater complete nail clearance when compared with etanercept in UNCOVER-2 and -3 (NCT01597245; NCT01646177) |
Secukinumab |
PsO and PsA |
Showed sustained efficacy in treating NP for up to 2.5 years in the TRANSFIGURE trial (NCT01807520) |
Brodalumab |
PsO |
Brodalumab showed an improved mean NAPSI score over ustekinumab in the AMAGINE-2 and -3 trials. |
Bimekizumab |
Showed better efficacy compared to placebo in the BE COMPLETE (NCT03896581) clinical trial at 16 weeks. |
|
Guselkumab |
PsO and PsA |
Positive NAPSI score and F-PGA responses at Week 16 in VOYAGE 1 and 2 (NCT02207231; NCT02207244) |
Risankizumab |
PsO and PsA |
In the KEEPsAKE1 (NCT03675308) trial, risankizumab treatment led to significant improvements in nail outcomes versus placebo in patients with NP. |
Tildrakizumab |
PsO |
No RCTs evaluating efficacy in nail disease. Some real-life experiences suggest it can improve NAPSI scores. |
F-PGA, Physician Global Assessment of Fingernail Psoriasis; NAPSI, Nail Psoriasis Severity Index; NP, nail psoriasis; PsA, psoriatic arthritis; PsO, psoriasis; RCT, randomized controlled trial. *Adapted from Battista, et al.2 and Drugs.com3,4 |
Table 3. Other therapies used for the treatment of nail psoriasis*
Therapy2 |
FDA Approved?3,4,5 |
Efficacy2 |
---|---|---|
Acitretin |
PsO |
Case studies suggest it can improve NP, but another study reported worsening of NP after acitretin. |
Methotrexate |
PsO |
In the METOP trial (NCT02902861), NP improved in some patients, although the improvement was slow. |
Cyclosporine |
PsO |
Studies show that cyclosporine has efficacy in treating NP; however, improvements may be greater when combined with a TNF-a inhibitor. |
Dimethylfumarate |
PsO |
Led to improvements in NP from baseline in the SKILL study. |
Phototherapy/ photochemotherapy |
PsO |
Studies have shown the nail plate completely blocks UVB radiation, and mostly blocks UVA, so phototherapy has low efficacy in NP. |
Apremilast |
PsO and PsA |
Apremilast improved NAPSI scores in NP in the ESTEEM 1 and 2 trials (NCT01194219; NCT01232283) from baseline to 16 weeks. |
NAPSI, Nail Psoriasis Severity Index; NP, nail psoriasis; PsA, psoriatic arthritis; PsO, psoriasis; TNF-a, tumor necrosis factor alpha; UVA, ultraviolet A; UVB, ultraviolet B. *Adapted from Battista, et al.2, Drugs.com3,4, and the National Psoriasis Foundation.5 |
Nail involvement in patients with psoriasis can be predictive of the severity of disease, and can lead to lower quality of life.1 Therefore, prompt treatment for nail psoriasis is important.1 There are multiple systemic treatments available which have shown efficacy in treating nail psoriasis, and treatment should be chosen based on patient characteristics, disease severity, joint involvement, and available guidelines.2 Additional studies, to compare efficacy and safety of treatments in nail psoriasis specifically, will improve knowledge and treatment options for these patients.
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox